281 related articles for article (PubMed ID: 12437671)
21. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
Green NS; Barral S
Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771
[TBL] [Abstract][Full Text] [Related]
22. Role of cyclic nucleotides in fetal hemoglobin induction in cultured CD34+ cells.
Keefer JR; Schneidereith TA; Mays A; Purvis SH; Dover GJ; Smith KD
Exp Hematol; 2006 Sep; 34(9):1151-61. PubMed ID: 16939808
[TBL] [Abstract][Full Text] [Related]
23. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
24. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
25. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
26. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
[TBL] [Abstract][Full Text] [Related]
28. Elevated fetal haemoglobin levels are associated with decreased incidence of retinopathy in adults with sickle cell disease.
Mian UK; Tang J; Allende APM; Heo M; Bernstein N; Vattappally L; Schoenfeld D; Minniti CP
Br J Haematol; 2018 Dec; 183(5):807-811. PubMed ID: 30417925
[TBL] [Abstract][Full Text] [Related]
29. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
Saleh AW; Hillen HF; Duits AJ
Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
[TBL] [Abstract][Full Text] [Related]
30. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
31. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea, sickle cell disease and renal transplantation.
Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
[No Abstract] [Full Text] [Related]
33. Cyclic Guanosine Monophosphate-Dependent Protein Kinase I Stimulators and Activators Are Therapeutic Alternatives for Sickle Cell Disease.
Ghanta M; Panchanathan E; Lakkakula BV
Turk J Haematol; 2018 Mar; 35(1):77-78. PubMed ID: 29192603
[No Abstract] [Full Text] [Related]
34. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
Keikhaei B; Yousefi H; Bahadoram M
Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
[TBL] [Abstract][Full Text] [Related]
35. Hydroxyurea and sickle cell disease: a chance for every patient.
Weiner DL; Brugnara C
JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
[No Abstract] [Full Text] [Related]
36. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea.
Glover RE; Ivy ED; Orringer EP; Maeda H; Mason RP
Mol Pharmacol; 1999 Jun; 55(6):1006-10. PubMed ID: 10347241
[TBL] [Abstract][Full Text] [Related]
37. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
[TBL] [Abstract][Full Text] [Related]
38. Long-term use of hydroxyurea for sickle cell anemia.
Hagar W
JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
[No Abstract] [Full Text] [Related]
39. Combined effects of arginine and hydroxyurea on BFU-E derived colony growth and HbF synthesis in erythroid progenitors isolated from sickle cell blood.
Baliga BS; Haynes J; Obiako B; Mishra N
Cell Mol Biol (Noisy-le-grand); 2010 Jun; 56 Suppl():OL1290-8. PubMed ID: 20937216
[TBL] [Abstract][Full Text] [Related]
40. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
